Literature DB >> 22670198

Seminal vesicle involvement by urothelial carcinoma in situ of the bladder with mucosal spread pattern: a case report.

Song-Yi Choi1, Ho-Chang Lee, Hyung Geun Song, Wun-Jae Kim, Ok-Jun Lee.   

Abstract

Mucosal spreading of urothelial tumors to the seminal vesicles is very rare. We experienced a case of mucosal involvement of the seminal vesicles by a bladder tumor in a 72-year-old man. The patient had a history of transurethral resection for invasive urothelial carcinoma of the bladder 8 years previously. Radical cystoprostatectomy was performed owing to recurrent and multiple urothelial carcinoma in situ. Microscopically, the urothelial carcinoma in situ was throughout the mucosa of the urinary bladder, both ureters, the prostate, and the left seminal vesicle. To date, the implication of mucosal involvement of the seminal vesicles by urothelial carcinoma is unclear. However, careful microscopic examination is needed to avoid an erroneous diagnosis.

Entities:  

Keywords:  Carcinoma in situ; Seminal vesicles; Urinary bladder neoplasms

Year:  2012        PMID: 22670198      PMCID: PMC3364478          DOI: 10.4111/kju.2012.53.5.368

Source DB:  PubMed          Journal:  Korean J Urol        ISSN: 2005-6737


  10 in total

1.  Primary seminal vesicle carcinoma: an immunohistochemical analysis of four cases.

Authors:  A H Ormsby; R Haskell; D Jones; J R Goldblum
Journal:  Mod Pathol       Date:  2000-01       Impact factor: 7.842

2.  Transitional cell carcinoma in situ of the seminal vesicles: 8 cases with discussion of pathogenesis, and clinical and biological implications.

Authors:  J E Montie; K Wojno; E Klein; C Pearsall; H Levin
Journal:  J Urol       Date:  1997-11       Impact factor: 7.450

3.  Primary squamous cell carcinoma of the seminal vesicle.

Authors:  Ken-ichi Tabata; Akira Irie; Daisuke Ishii; Nobuyuki Yanagisawa; Masatsugu Iwamura; Shiro Baba
Journal:  Urology       Date:  2002-03       Impact factor: 2.649

4.  Outcome in patients with seminal vesicle invasion after radical cystectomy.

Authors:  Björn G Volkmer; Rainer Küfer; Simone Maier; Georg Bartsch; Dietmar Bach; Richard Hautmann; Jürgen E Gschwend
Journal:  J Urol       Date:  2003-04       Impact factor: 7.450

5.  Transitional cell carcinoma involving the prostate with a proposed staging classification for stromal invasion.

Authors:  D Esrig; J A Freeman; D A Elmajian; J P Stein; S C Chen; S Groshen; A Simoneau; E C Skinner; G Lieskovsky; S D Boyd; R J Cote; D G Skinner
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

Review 6.  Pseudoneoplastic mimics of prostate and bladder carcinomas.

Authors:  Omar Hameed; Peter A Humphrey
Journal:  Arch Pathol Lab Med       Date:  2010-03       Impact factor: 5.534

7.  Seminal vesicle involvement by in situ and invasive transitional cell carcinoma of the bladder.

Authors:  J Y Ro; A G Ayala; A el-Naggar; K I Wishnow
Journal:  Am J Surg Pathol       Date:  1987-12       Impact factor: 6.394

8.  Prognosis of seminal vesicle involvement by transitional cell carcinoma of the bladder.

Authors:  Siamak Daneshmand; John P Stein; Timothy Lesser; Marcus L Quek; Peter W Nichols; Gus Miranda; Jie Cai; Susan Groshen; Eila C Skinner; Donald G Skinner
Journal:  J Urol       Date:  2004-07       Impact factor: 7.450

9.  [Monstrous epithelium in the seminal vesicles and epididymis].

Authors:  B Habanec
Journal:  Cesk Patol       Date:  1984-05

10.  Incidence and location of prostate and urothelial carcinoma in prostates from cystoprostatectomies: implications for possible apical sparing surgery.

Authors:  Monica P Revelo; Michael S Cookson; Sam S Chang; M Frances Shook; Joseph A Smith; Scott B Shappell
Journal:  J Urol       Date:  2004-02       Impact factor: 7.450

  10 in total
  1 in total

1.  Seminal Vesicle Involvement by Carcinoma In Situ of the Bladder: Clonal Analysis Using Next-Generation Sequencing to Elucidate the Mechanism of Tumor Spread.

Authors:  Hyun Sik Park; Hyun Bin Shin; Myung-Shin Lee; Joo Heon Kim; Seon-Young Kim; Jinsung Park
Journal:  Cancer Res Treat       Date:  2020-03-19       Impact factor: 4.679

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.